The salvage of recurrent endometrial carcinoma in the vagina and pelvis

Int J Radiat Oncol Biol Phys. 1988 Oct;15(4):809-13. doi: 10.1016/0360-3016(88)90111-3.

Abstract

A retrospective analysis was performed on 93 patients who developed recurrent endometrial carcinoma in the pelvis, vaginal vault, and lower 1/3 vagina. There were 12 lower 1/3 vaginal recurrences, 24 vault recurrences and 57 pelvic recurrences from the 1005 patients treated between 1960 and 1976. Median time to recurrence was 30 months. Twenty-six patients had distant metastases also present at the time of recurrence in the sites mentioned above. Thirty-three percent of lower 1/3 vaginal recurrences, 12.5% of vault recurrences, and 5.3% of pelvic recurrences were salvaged with further treatment. The 10-year actuarial survival rates of isolated lower 1/3 vaginal, vaginal vault, and pelvic recurrences were 50%, 45%, and 24% respectively.

MeSH terms

  • Adenocarcinoma / radiotherapy
  • Adenocarcinoma / secondary
  • Carcinoma, Squamous Cell / radiotherapy
  • Carcinoma, Squamous Cell / secondary
  • Combined Modality Therapy
  • Female
  • Humans
  • Pelvic Neoplasms / radiotherapy
  • Pelvic Neoplasms / secondary*
  • Prognosis
  • Uterine Neoplasms / radiotherapy
  • Uterine Neoplasms / surgery*
  • Vaginal Neoplasms / radiotherapy
  • Vaginal Neoplasms / secondary*